Clinical Trial Update: Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1) [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 long-term safety and efficacy study of alpelisib in patients with PIK3CA-related overgrowth spectrum (PROS) who p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pik3ca-related Overgrowth Spectrum

Drugs mentioned

• Alpelisib (alpelisib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: PIK3CA-related Overgrowth Spectrum (PROS) | Phase 2 | Status: ACTIVE_NOT_RECRUITING